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Abstract—While myalgic encephalomyelitis/chronic fatigue 
syndrome (ME/CFS) is relatively new and poorly understood, a 
recent upsurge in research has identified the disease’s core 
symptoms, including post-exertional malaise and orthostatic 
intolerance. The FDA has yet to approve any treatments for 
ME/CFS, partially due to a lack of validated efficacy endpoints. 
 
The central focus of this research is to develop ME/CFS 
efficacy endpoints using a non-invasive, inertial measurement-
based approach. Accessible endpoints will provide a way to 
properly evaluate potential treatments for ME/CFS. Using a 
Kalman filter, inertial measurement unit (IMU) data can be 
converted to optimized leg angle estimates. These angle estimates 
can then be converted to personalized daily measurements of 
upright activity, referred to as uptime.  
 
In a six-day, case-control study conducted by the Bateman 
Horne Center, uptime was measured for 15 subjects (five controls, 
five moderate-level ME/CFS, and five severe-level ME/CFS). 
Analysis of these uptime scores indicated that each group spends 
different proportions of their days upright and active. This result 
shows that uptime can accurately determine disease severity and is, 
therefore, a reliable endpoint for evaluating ME/CFS treatment 
efficacy. 
NOMENCLATURE 
𝜙 Roll, angle relative to a global x-axis  
𝜃 Pitch, angle relative to a global z-axis 
𝜓 Yaw, angle relative to a global y-axis 
𝑎𝑥 Acceleration along the x-axis 
𝑎𝑦 Acceleration along the y-axis 
𝑎𝑧 Acceleration along the z-axis 
𝑝 Body fixed rotation rate about the x-axis 
𝑞 Body fixed rotation rate about the y-axis 
𝑟 Body fixed rotation rate about the z-axis 
𝜃𝑐 Critical angle, measured from vertical 
I. INTRODUCTION 
 More than two million Americans suffer from myalgic 
encephalomyelitis/chronic fatigue syndrome (ME/CFS), with an 
annual cost of $24 billion [1][2]. While our understanding of the 
etiology of ME/CFS is currently incomplete, studies have shown 
that the disease commonly occurs following viral infection and 
other acutely stressful events, impacting women more frequently 
than men at a rate of 6:1 [3]. A recent upsurge in ME/CFS 
research has led to an understanding of the disease’s core 
symptoms: (1) fatigue as a response to physical exertion, (2) 
post-exertional malaise (PEM), (3) unrefreshing sleep, (4) 
cognitive impairment, and (5) orthostatic intolerance (OI) [4]. 
While the scientific community’s understanding of ME/CFS is 
continuously improving, no cure has been discovered. Patients 
often suffer from ME/CFS for years, and sometimes even until 
death [5]. 
PEM causes individuals with ME/CFS to become 
disproportionately fatigued following mental or physical 
exertion. It is regarded as the distinctive symptom of ME/CFS 
[6]. As a result of PEM, individuals with ME/CFS can have 
difficulty performing mundane tasks such as routine cleaning, 
grocery shopping, and even showering.  
OI refers to the onset of symptoms that occur when standing 
upright; these symptoms can be alleviated by reclining. While 
the exact cause of OI remains unknown, Dr. van Campen’s 
research suggests that significantly lower blood volume is 
common among adults with ME/CFS who experience OI [7]. 
Sub-normal blood volume is likely the cause of the circulation-
related issues many ME/CFS patients endure, such as dizziness, 
headaches, weakness, and nausea. These are the most common 
symptoms of OI, all of which occur as a result of prolonged 
upright posture. 
The FDA has yet to approve any treatments—physical or 
pharmaceutical—for ME/CFS. To some extent, this lack of 
FDA-approved treatments is due to a lack of validated efficacy 
endpoints [4]. Efficacy endpoints are used in clinical trials to 
reliably monitor the improvement of subjects as a result of a 
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prescribed treatment. In recent years, researchers have developed 
some ME/CFS efficacy endpoints using blood tests [8] and other 
invasive methods [9]. The central focus of this research is to 
develop efficacy endpoints using a completely non-invasive, 
inertial measurement-based approach. More accessible efficacy 
endpoints will provide a way to properly evaluate potential 
treatments for ME/CFS, especially if these endpoints correspond 
to the disease’s core symptoms. 
Researchers at the Bateman Horne Center (BHC) in Salt 
Lake City, Utah recently discovered an endpoint that shows 
promise as a reliable assessment of functional impairment 
among patients with ME/CFS. In studies conducted by the BHC, 
subjects were asked to fill out questionnaires, identifying how 
much time they spent upright during the previous 24 hours. The 
BHC refers to this measurement of uprightness as hours of 
upright activity (HUA).  
Due to its strong correlation with PEM, HUA is a simple 
way to gauge disease severity among individuals with ME/CFS 
(transcript in progress). While HUA is a valuable efficacy 
endpoint, its deficiencies are significant. The primary weakness 
of HUA is the inaccuracy of its current data collection method—
questionnaire [10]; it is unreasonable to expect patients to 
accurately recall the amount of time they spent in an upright 
position the previous day. Another weakness of HUA is the low 
resolution offered by the measurement. “Hours” of upright 
activity is just that, a measurement recorded as whole integers in 
units of hours. Due to the inaccuracy and low resolution of data 
collected from HUA questionnaires, the only way to obtain a 
measurement of upright activity with a higher level of precision 
involves significant alterations to the current measurement 
process.  
To address HUA’s shortcomings, an improved method for 
evaluating upright activity is proposed. Using an inertial 
measurement unit (IMU), it is possible to continuously and 
accurately measure upright activity, thus providing an effective 
method to assess disease severity among individuals with 
ME/CFS. By continuously measuring the uprightness of the 
lower legs, we can obtain a measurement referred to as uptime. 
The advantages of this approach are two-fold. The first 
advantage is that healthcare providers will no longer need to rely 
upon the accuracy of a patient’s memory to approximate upright 
activity. The second advantage comes from increasing the 
resolution of the measurement from hours—HUA—to 
seconds— uptime. 
The goal of our research is to validate an improved method 
to assess upright activity. To formally evaluate uptime as an 
efficacy endpoint for ME/CFS disease severity, this research 
evaluates the results of a study wherein a healthy control group 
and an experimental group of ME/CFS patients were outfitted 
with Shimmers—a commercially available IMU—for six 
consecutive days. During these six days, the Shimmers 
continuously measured uptime. Statistical tests and other 
comparisons were used to evaluate the correlation between data 
collected by the Shimmer and uptime.  
Our research simplifies symptom severity evaluation among 
patients with ME/CFS. As a result, assessing the long-term 
efficacy of treatments for patients with ME/CFS will 
significantly improve the evaluation of disease severity in terms 
of both ease and accuracy. These changes will enable the 
development of effective treatments, thus providing a path to 
recovery for individuals struggling with ME/CFS. 
II. MATERIALS AND METHODS 
The chief objective of this research is to evaluate uptime to 
prove its value as an efficacy endpoint for ME/CFS. We 
accomplished this goal in three steps: (1) establish a method to 
measure lower leg angle using an IMU, (2) verify the accuracy 
of these IMU-based angle measurements, and (3) perform a case-
control study comparing uptime between different ME/CFS and 
non-ME/CFS groups. 
A.  Uptime Calculation – IMU Sensor Fusion  
Calculating uptime is a two-step process. First, we measure 
lower leg angle by filtering IMU data. Second, we evaluate this 
measured angle to determine if the leg is upright. Distinguishing 
leg uprightness is crucial because it relates to the HUA 
questionnaire, which quantifies daily time spent in upright 
postures (see Fig. 1). 
 
 
Fig. 1.  HUA survey—HUA-based estimates of uptime are calculated by 
summing the time spent with feet on the floor. 
To replace the HUA questionnaire, we chose to calculate 
uptime using an IMU placed on each lower leg. Lower leg angles 
allow us to accurately assess whether the feet are on the floor 
(lower legs vertical) or off the floor (lower legs 
reclined/horizontal) while maximizing user comfort. 
The Shimmer, a commercially available IMU, was selected 
for use in this research due to its small and lightweight design, 
data logging capacity, ample battery life, and previous use in 
related work [11][12]. Using an internal SD card, the Shimmer 
can simultaneously record accelerometer, gyroscope, and 
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magnetometer data for extended periods. Accurate angle 
estimations can be obtained using only the accelerometer and 
gyroscope. 
Combining data from multiple sensors, otherwise known as 
sensor fusion, has been extensively reviewed in the literature 
[13]. Sensor fusion reduces measurement uncertainty by 
merging data from multiple sensors. Our sensor fusion method 
of choice, the Kalman filter, was used to merge the Shimmer’s 
raw accelerometer and gyroscope data to determine lower leg 
angle, measured from vertical. 
Estimates of lower leg angle can be derived from both the 
accelerometer and the gyroscope. Equations 1 and 2 show 
estimates of roll (𝜙) and pitch (𝜃) calculated from accelerometer 
data (𝑎𝑥, 𝑎𝑦, and 𝑎𝑧) using trigonometry. 
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Equation 3 shows how lower leg angle rates were estimated by 
transforming raw gyroscope data (𝑝, 𝑞, and 𝑟) into global frame 
Euler angle rates, which were subsequently integrated to form 
angle estimates. 
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Both angle estimates were optimally combined using a Kalman 
filter to minimize measurement noise and bias error.  
A custom MATLAB function calculated uptime by 
comparing the Kalman filter’s optimized lower leg angle 
estimates to a critical angle. The role of the critical angle is to 
mark the difference between a lower leg that is upright and one 
that is not upright (see Fig. 2). 
 
 
Fig. 2.  The angle of each lower leg is compared to the critical angle (𝜃𝑐) to 
determine uprightness. 
For our research, the critical angle was set equal to 39 degrees 
from vertical. After determining each leg’s “uprightness,” our 
MATLAB function calculated uptime as a percentage of the day 
spent with the lower legs in an upright position. 
B.  IMU-Based Uptime Accuracy Confirmation  
To confirm the accuracy of the filtered lower leg angles, we 
performed a small study using a nine-camera VICON motion 
capture system as a 100% accurate reference for comparison. 
The Shimmer’s low-noise accelerometer was set to an output 
range of ± 2 g, and the gyroscope was set to an output range of ± 
500 deg/sec. 
The VICON and Shimmer systems were then 
simultaneously used to measure lower leg angles while three 
subjects followed a series of postures, holding each for 
approximately five seconds (Fig. 3). 
 
 
Fig. 3.  Sequence of postures imitated by subjects during accuracy confirmation 
study. 
This sequence of postures was explicitly developed to push the 
limits of the Shimmer’s motion capture abilities and encompass 
the full range of lower leg angles that would be seen in a week-
long study, from vertical to horizontal. 
Both the VICON and Shimmer systems collected data at a 
sample rate of 30 Hz. When comparing VICON angles to 
Shimmer angles, root mean squared error (RMSE) calculations 
showed that the two measurements differed by an average of 
0.53 degrees for all three subjects. RMSE was 0.80 degrees for 
subject 1, 0.13 for subject 2, and 0.66 for subject 3. Most error 
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Fig. 4.  Comparison of angle data from VICON and Shimmers for one subject. 
Uptime was calculated twice for each subject—once using 
VICON angles and once using Shimmer angles. When reviewing 
uptime scores for all three subjects, we found that the Shimmer 
had an average error of 1.88% when compared to the VICON 
system (Table 1). 
TABLE 1.  UPTIME DATA FOR BOTH THE VICON SYSTEM AND THE SHIMMER 
System 
Uptime (%) 
Subject 1 Subject 2 Subject 3 
VICON 29.61 31.47 24.79 
Shimmer 29.74 30.67 25.45 
Error 2.54% 0.42% 2.67% 
 
This small amount of error was deemed negligible for our 
application. Subject-to-subject differences in measurement 
accuracy were also acceptably low. 
C.  Case-Control Study Design 
For the planned case-control study, a total of 15 subjects 
were outfitted with a Shimmer on each ankle. Each subject wore 
both devices for six days—starting on a Monday and ending on 
a Saturday. The 15 subjects were divided into three groups based 
on disease level: (1) five subjects without ME/CFS (the 
controls), (2) five subjects with moderate-level ME/CFS, and (3) 
five subjects with severe-level ME/CFS. Due to limited Shimmer 
availability, data collection was staggered so that one or two 
subjects participated each week.  
The six-day data collection period was broken into two 
phases. Phase one began on a Monday (when the subject traveled 
to the BHC to be outfitted with the Shimmers) and ended 72 
hours later—the following Thursday. Phase two began on 
Thursday (where phase one ended) lasting another 72 hours 
before ending on Sunday. 
The data collected during phase one was meant to be a 
baseline against which the data from phase two would be 
compared; at the beginning of phase two, each subject performed 
the NASA 10-minute Lean Test—meant to cause the onset of 
PEM for subjects with ME/CFS, but have no effect on the control 
group. Subjects were instructed to go about their lives in a 
normal manner during the study. 
III. RESULTS AND DISCUSSION 
A.  Uptime Differences Between Disease Groups  
Due to differences in activity levels brought on by the 
presence and severity of ME/CFS, we expected the control group 
to have the highest uptime and the severe ME/CFS group to have 
the lowest uptime, with the moderate ME/CFS group’s uptime 
somewhere in the middle. Group trends for weekly average 
uptime scores supported this expectation.  
Controls generally had average weekly uptimes above 30%. 
Subjects with moderate ME/CFS generally had uptimes between 
20 – 30%. Subjects with severe ME/CFS averaged daily uptime 
scores below 20%. The non-overlapping group confidence 
intervals (shown by the vertical colored lines in Fig. 5) are 
evidence indicating that uptime differs by disease level.  
 
 
Fig. 5.  Mean plot of uptime separated by disease level. 
The results of an ANOVA test further substantiated these 
group uptime differences, confirming that uptime differs 
significantly between the groups (Table 2). 










F value P-value 
Disease 
Level 
2 8570 4285 61.535 1.9e-15*** 
Day 5 505 101 1.450 0.219 
Subject 12 2284 190 2.733 0.005** 
Residuals 64 4317 70 - - 
* Significance codes:  0 ‘***’  0.001 ‘**’     0.01 ‘*’      0.05 ‘.’      0.1 ‘ ’ 
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The null hypothesis of this ANOVA test is that the mean 
uptime is the same for all groups. A p-value of 1.9e-15 shows 
that there is insufficient evidence to support the null hypothesis 
(at the significance level 𝛼 = 0.05). As a result, we accept that 
the alternative is true, indicating that there is a difference 
between the mean group uptimes.  
To further expand upon the result of this ANOVA, we used 
Tukey’s HSD (honestly significant difference) test. Up to this 
point, we have only shown that mean group uptimes are not all 
equal. Tukey’s HSD test identified which specific group 
differences exist. For all pairs of means, the calculated p-values 
are far less than 𝛼 = 0.05, meaning that each group’s mean 
uptime is different from all other groups (Table 3). 
TABLE 3.  TUKEY’S HSD TEST COMPARING UPTIME BY DISEASE GROUP 
Disease 
Level 





-12.19 -18.17 -6.20 2.13e-05*** 
Severe-
Control 
-25.54 -31.82 -19.25 0.00e+00*** 
Severe-
Moderate 
-13.35 -19.64 -7.06 9.80e-06*** 
* Significance codes:  0 ‘***’   0.001 ‘**’     0.01 ‘*’      0.05 ‘.’      0.1 ‘ ’ 
With the combined results of the mean plot, ANOVA test, 
and Tukey’s HSD test, we can confidently state that uptime 
differs for all disease levels. Using the uptime scores collected 
from all 15 subjects, we can define the uptimes expected for each 
group. Controls (non-ME/CFS individuals) are expected to have 
weekly uptime scores above 30%. Patients with moderate 
ME/CFS are expected to have weekly uptime scores between 
20% and 30%. Patients with severe ME/CFS are expected to 
have weekly uptime scores below 20% (Fig. 6). 
 
  
Fig. 6.  Subject weekly average uptime scores (left) and corresponding scale of 
expected uptime scores for each disease group (right). 
These conclusions align with the observations of the BHC 
and their understanding of ME/CFS. Symptoms of this disease—
such as post-exertional malaise (PEM) and orthostatic 
intolerance (OI)—limit a patient’s ability to remain upright. As 
disease severity increases, so do these physical limitations. 
Therefore, we can objectively conclude that uptime corresponds 
to the presence and severity of ME/CFS. 
B.  Uptime Before vs. After NASA Lean Test 
Next, we looked for uptime differences before and after the 
NASA Lean Test. The NASA 10-minute Lean Test requires 
subjects to stand straight upright and lean against a wall, with 
only the shoulder blades contacting the wall, and heels six inches 
from the wall [14]. This test was expected to induce Post-
Exertional Malaise (PEM) in subjects with ME/CFS, thereby 
decreasing subsequent uptime scores. 
In this comparison, a baseline uptime score was calculated 
by averaging the three days before the NASA Lean Test: 
Monday, Tuesday, and Wednesday. This baseline was used for 
comparison when reviewing uptime scores for the proceeding 
days: Thursday, Friday, and Saturday. Therefore, the variable 
“Number of Days after Lean Test” has the following levels: 
• Baseline (average uptime for Monday, Tuesday, and 
Wednesday) 
• 1 Day after Lean Test (Thursday’s uptime) 
• 2 Days after Lean Test (Friday’s uptime) 
• 3 Days after Lean Test (Saturday’s uptime) 
Despite our expectations, uptime averages for each group, 
shown in Fig. 7, do not decrease following the Lean Test. 
Instead, mean uptimes for ME/CFS groups spike one day after 
the test.  
 
 
Fig. 7.  Group mean plots for uptime. 
Interestingly, the control group alone decreases after the 
Lean Test; however, this change is due to weekend relaxation 
rather than the effects of the NASA Lean Test. Furthermore, the 
ME/CFS groups’ uptime spikes could have been a direct result 
of participating in the NASA Lean Test. A 5-10% increase in 
uptime equals roughly 1-2 hours of upright activity. This 
increase could easily be the amount of time required to drive to 
the BHC, take the Lean Test, and drive home. 
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Because the confidence intervals in Fig. 7 overlap so 
heavily, we don’t expect to find any significant difference in 
mean uptimes before and after the NASA Lean Test. This 
suspicion is confirmed by the high p-values shown in Table 4, 
which indicate that there are no significant differences in uptime 
by day. 




















3 630 210.0 1.658 0.218 












3 58.8 19.59 0.431 0.734 







 Days After 
Lean Test 
3 167.4 55.80 0.905 0.465 
Residuals 15 801.5 61.65 - - 
* Significance codes:  0 ‘***’   0.001 ‘**’     0.01 ‘*’      0.05 ‘.’      0.1 ‘ ’ 
With the results of Table 4, we find ourselves forced to 
reject the consensus that activity decreases after the NASA Lean 
Test. This finding can be explained in a few different ways. For 
one thing, our experimental design was not without flaws. On the 
first day of each trial, the subject traveled to and from the BHC 
to be equipped with the Shimmers. Due to the extreme sensitivity 
of ME/CFS patients, this travel alone could have unintentionally 
induced PEM. With patients experiencing PEM throughout the 
entirety of the study (rather than just during days 4 through 6), 
we would expect to see constant uptime scores. Future studies 
should consider home-visits to reduce this effect. 
The floor effect could be an alternative explanation for these 
unexpected results; uptime can only go so low. Baseline uptimes 
for the ME/CFS groups could already be at minimum allowable 
levels. Further uptime reductions could mean a significant 
decrease in lifestyle. (The quality of life for an individual with 
ME/CFS is already very low). Some subjects in the moderate 
ME/CFS group have part-time jobs; taking a few days off to 
recover from PEM may not be an option. For the severe ME/CFS 
group, it simply may not be possible to lower uptime from their 
average four hours per day. 
Lastly, constant ME/CFS uptime scores could be a result of 
self-medication. Except for the morning of the Lean Test, 
ME/CFS subjects were permitted to take their prescribed 
medication throughout the study. Subjects may have medicated 
more heavily following the NASA Lean Test to mitigate the 
effects of PEM, thus unintentionally flattening uptime.  
Whatever the reason, it is indisputable that the NASA Lean 
Test had no statistically significant effect on uptime. A better 
experiment design would track each subject for a more extended 
period before and especially after the NASA Lean Test, thus 
establishing more accurate baseline uptime scores for each 
subject. However, limitations in funding and time prohibited 
these design improvements. Further investigation but may 
provide deeper insight into the causes and effects of PEM. 
C.  Comparison of HUA and Uptime 
Finally, we turn to an evaluation of HUA as a proxy for 
IMU-based uptime scores. Until this study, the only tool 
researchers at the BHC had to evaluate daily upright activity was 
HUA—a questionnaire that crudely captures the amount of time 
an individual spends with the feet on the floor each day. 
Historically, HUA was reported in units of hours; however, we 
have converted HUA to a percentage of the day to accommodate 
its comparison to IMU-based uptime measurements. 
During our case-control study, subjects filled out daily HUA 
questionnaires. The results of these surveys show that subjects 
generally tend to overestimate uptime (Fig. 8). 
 
 
Fig. 8.  HUA and uptime compared for the study’s combined ninety days of data. 
Control subject data are included as indices 1-30, moderate ME/CFS data are 
included as indices 31-60, and severe ME/CFS data are included as indices 61-
90. An index where uptime is not shown indicates a lack of Shimmer data. 
Indeed, a correlation plot—broken up by disease level—
shows that HUA and uptime are not correlated for both ME/CFS 
groups (Fig. 9). 
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Fig. 9.  Correlation plots between uptime and HUA, separated by disease level. 
Both ME/CFS groups reported a wide range of HUA scores, 
while uptime remained relatively invariant. This non-correlation 
is illustrated by the horizontal grey and red lines in Fig. 9. 
Conversely, the control group estimated uptime with some level 
of accuracy. We see a positive, linear correlation between uptime 
and HUA for this group shown by the blue line in Fig. 9. 
However, a multitude of blue outliers suggests the weakness of 
this correlation. 
A paired t-test comparing all HUA and uptime scores 
yielded a p-value of 2.72e-05, confirming that the two 
measurement types produce significantly different scores. The 
corresponding 95% confidence interval for the true mean 
difference is (4.17, 10.91). This interval indicates that we are 
95% confident that the average difference between HUA and 
uptime is between 4.17 and 10.91%.  
IV. CONCLUSION 
This research proves the value of uptime as an objective 
replacement for HUA. Analysis of collected uptime data 
indicates that disease groups spend different proportions of the 
day upright and active. Healthy individuals are expected to have 
weekly uptime scores above 30%, subjects with moderate 
ME/CFS are expected to have weekly uptime scores between 
20% and 30%, and subjects with severe ME/CFS are expected to 
have weekly uptime scores below 20%. 
Another objective of our study was to evaluate the effects of 
PEM brought on by the NASA Lean Test. Our results showed no 
change in uptime after the NASA Lean Test. Although this 
contradicts our expectations, we have confirmed that this test is 
humane; patients with ME/CFS do what they can to avoid stress-
causing exertion, but we have seen that this test does not cause a 
drastic decrease in uptime—indicating that they aren’t 
significantly hurt by the test. Future studies should incorporate 
home-visits to reduce the stress caused by participation, thereby 
ensuring that PEM is only induced by researchers during the 
Lean Test. 
Accurate uptime measurements will become invaluable for 
healthcare providers in assisting ME/CFS patients. Furthermore, 
uptime provides a method for pharmaceutical companies and 
independent researchers to prove the efficacy of their 
treatments—a critical step towards receiving FDA-approval. The 
BHC’s data shows that patients with severe ME/CFS are limited 
to a bed or reclining chair for all but five hours each day; 
increasing this number would be life-changing. 
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